Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Pilot Phase II Chemotherapy with Guanazole for Stage III Unresectable Carcinoma of the Lung

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Closed

no age specified

SEG-LUN-P40

Objectives

I.   Determine the effectiveness of guanazole in the treatment of Stage III 
lung cancer of all cell types by measuring objective response, duration of 
response, and survival.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with microscopically proven 
bronchogenic carcinoma of all cell types with Stage III disease including at 
least one measurable or evaluable lesion.  Patients must have adequate renal, 
hepatic, and marrow function and a performance status of 3 or better on the 
Zubrod scale.  Patients may not have had prior therapy with ARA-C or 
hydroxyurea.  There may be no concurrent second tumor, except for 
well-controlled basal cell carcinoma, and patients may not be pregnant.  
Patients with small cell carcinoma must have had prior treatment.

Expected Enrollment

About 30 patients will be entered (4 as of November 1981).  Protocol closed 
August 1983.

Outline

Nonrandomized study.
Single-agent Chemotherapy.  Guanazole, NSC-1895.

Published Results

Krauss S, Broder LE, Birch R: Guanazole in the treatment of advanced bronchogenic carcinoma: a pilot study of the Southeastern Cancer Study group. Cancer Treat Rep 70(7): 913-914, 1986.

Trial Contact Information

Trial Lead Organizations

Southeastern Cancer Study Group

George A. Omura, MD, Protocol chair
Ph: 205-444-4617

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.